Fig. 1
DIC classification. DIC in COVID-19 has previously been discussed exclusively in terms of suppressed-fibrinolytic-type DIC. However, enhanced fibrinolysis results in fatal bleeding, and it therefore requires the planning of anticoagulant therapy that accurately assesses the moment by moment changes in coagulation and fibrinolysis abnormalities. TAT, thrombin-antithrombin complex; PIC, plasmin-α2 plasmin inhibitor complex; PAI, plasminogen activator inhibitor; APL, acute promyelocytic leukemia. This figure was previously published by one of the authors (Asakura, 2014) [14] and modified for this manuscript